BioClavis has announced the planned creation of 43 new jobs with a £10.5 million investment supported by Scottish Enterprise.
Bioclavis is a new spin-out from Californian molecular profiling company Biospyder, to be based at the Clinical Innovation Zone at Glasgow’s Queen Elizabeth University Hospital, creating 43 new jobs.
BioSpyder’s investment has been supported by a £4.5m Seek & Solve research and development grant from Scottish Enterprise. It forms part of a total investment of £10.5m, which will see BioClavis adapt BioSpyder’s TempO-Seq platform technology into a novel diagnostic tool for precision medicine in a number of high value clinical indications, in close collaboration with the health service and university researchers.
Joel McComb, CEO of BioSpyder and BioClavis said: “We’re very excited to build on the success we’ve had in other molecular profiling applications and bring this novel method to bear on discovery and deployment of next generation genomic diagnostics.
“We determined Glasgow, Scotland to be the ideal location for this initiative based in large part on the support and close working relationships with Scottish Enterprise, NHS and the University.”
ibis Styles Glasgow Centre West has opened in Glasgow’s International Financial Services District (IFSD) following an £11.25 million investment led...Read More
The University of Strathclyde’s Advanced Forming Research Centre (AFRC) has secured £16.5 million to establish a major new advanced...Read More
Motel One has opened its newest hotel in Glasgow which is also now Scotland’s largest The new Motel One...Read More
Sign-up to our email updates for the latest investment opportunities and information in Glasgow. Fill out the form below with your email.
